Spotting the wood from the trees
It’s time to turn our attention to the annual AACR-NCI-EORTC international conference on molecular targets and cancer therapeutics, often dubbed simply as TARGETS or TRIPLE for many industry observers.
Spotting the wood from the trees
With the ongoing pandemic, this year’s meeting remains a virtual one and runs from today through Sunday.
There’s quite a lot of intriguing abstracts to cover this year so we kick off our coverage with a look at KRAS combinations.
While the single agent activity of both sotorasib and adagrasib has been encouraging in lung cancer with G12C mutations, the rest test was always going to be what combinations will emerge as winners in terms of overcoming primary or acquired resistance (the mechanisms might be different in each case) in order to improve outcomes further.
Any agent targeting the MAPK pathway will necessarily be challenging in combination with KRAS inhibitors due to toxicities, but are there other approaches or could we finesse the dosing/schedules more optimally?
Here we look at two such combination strategies to see how they are faring…
BSB subscribers can read up on our latest commentary and analysis from the cancer conference season as we begin our TRIPLE meeting coverage – you can log-in or click to access our latest analysis.
This content is restricted to subscribers
In the past, much of the focus at previous American Society of Hematology (ASH) meetings in this area has focused on the myriad of chemotherapy regimens and dose/schedule optimisations that followed in trying to boost patient outcomes.